Zymergen Inc. (ZY) News

Zymergen Inc. (ZY): $3.37

0.26 (+8.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ZY to Watchlist
Sign Up

Industry: Chemicals


Ranked

of 89

in industry

Filter ZY News Items

ZY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ZY News Highlights

  • For ZY, its 30 day story count is now at 3.
  • Over the past 29 days, the trend for ZY's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about ZY are DECK.

Latest ZY News From Around the Web

Below are the latest news stories about Zymergen Inc that investors may wish to consider to help them evaluate ZY as an investment opportunity.

What You Need To Know About Zymergen Inc.'s (NASDAQ:ZY) Investor Composition

A look at the shareholders of Zymergen Inc. ( NASDAQ:ZY ) can tell us which group is most powerful. Insiders often own...

Yahoo | February 22, 2022

Zymergen (ZY) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

The following slide deck was published by Zymergen Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 24, 2022

Zymergen debuts Automation business and shares program portfolio

Zymergen (ZY) announces a new Automation business and updated portfolio

Seeking Alpha | January 11, 2022

Zymergen Debuts Automation Business and Shares Program Portfolio at 40th Annual JP Morgan Healthcare Conference

Delivering platform expertise and developing novel microbes, molecules and materials for customers across a variety of marketsSAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen (ZY) today announced a new Automation business and updated portfolio, further refining the company’s focus on high-value solutions where its proprietary platform can provide distinct advantages. Zymergen’s Automation business delivers proven automation technology to organizations interested in

Yahoo | January 11, 2022

Zymergen Announces Emerging Drug Discovery Business Enabled by One of the World’s Largest Metagenomics Databases and Proprietary Synthetic Biology Platform

Exploring natural products for innovative therapeuticsSAN FRANCISCO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen (ZY) announced a new drug discovery business based around their proprietary synthetic biology platform and what is believed to be the world’s largest metagenomics database, combining both size and quality. This new business leverages Zymergen’s differentiated access to natural products as a source of diverse chemical matter and augments Zymergen’s existing advance

Yahoo | January 10, 2022

Mesabi Trust registers biggest gain; Amyris slips to bottom

Mesabi Trust (MSB) +13.15%, Largo Resources (LGO) +12.15%, Amyris (AMRS) -19.40%, Zymergen (ZY) -14.95%

Seeking Alpha | January 8, 2022

Zymergen to Present at the 40th Annual J.P. Morgan Healthcare Conference

EMERYVILLE, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen"or the "Company"), today announced the company will be participating in the upcoming 40 th Annual J.P. Morgan Virtual Healthcare Conference. Zymergen''s management is scheduled to present on Full story available on Benzinga.com

Benzinga | January 5, 2022

Year in Review: From Elizabeth Holmes trial to Zymergen's tribulation — and then there's this pandemic

In a year when the Covid-19 pandemic and its variants were mostly kept at bay by the Bay — relative to other parts of the country at least — the biotech and health news flow didn't slow. Here's a quick look at the stories that made the cut: With a $575 million IPO in April, Zymergen Inc. (NASDAQ: ZY) was the poster child for synthetic biology. Suffice it to say, I thank my colleague Cromwell Schubarth for falling on the sword of the Elizabeth Holmes fraud trial.

Yahoo | December 22, 2021

Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies

- Business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common stock Private Investment in Public Equity (“PIPE”) financing and from non-redemption agreements - - Over $86 million in non-redemption agreements committed from existing Dynamics investors including funds managed by ARK Investment Management LLC, funds and accounts managed by Counterpoint Global (Morga

Yahoo | December 20, 2021

ZYMERGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Zymergen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zymergen Inc. (NASDAQ: ZY) on behalf of long-term stockholders following a class action complaint that was filed against Zymergen on August 4, 2021. Our investigation concerns whether the board of directors of Zymergen have breached their fiduciary duties to the company. The complaint alleges that the Registration Statement was ma

Yahoo | December 16, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5874 seconds.